|Catherine Beaucé (Chair)||Sanofi - France|
|Rebecca Leyland||AstraZeneca - UK|
|Boris Czekay||Bayer Healthcare - Germany|
|Christine Klein||Boehringer Ingelheim GmbH - Germany|
|Isabelle deLacroix Vaubois||Pfizer - France|
|Ran Song||Takeda Pharmaceuticals|
|Henrik Schwaighofer||Fresenius Kabi - Germany|
|Markus Lyga||Merck KGaA - Germany|
|Christopher Wooden||IQVIA - France|
|Jeremy Hillman||IQVIA - UK|
|Clare McGettigan||Kantar Health|
Ensure databases & systems provide the best suitable platform to do international secondary market research through partnership with the major global providers.
The Committee consists of pharmaceutical international market research representatives and IMS representatives. Project teams may be formed to address specific needs and other providers may be invited to participate whenever appropriate. The Committee always welcomes new members from pharmaceutical industry to enlarge its knowledge & experience sharing.
12 to 15 pharmaco’s members are the optimum to ensure good coverage of business needs, to maximise the sharing of experiences and to still allow open and constructive discussions with our Committee partnerships with IQVIA.
Membership of Committee is restricted to EphMRA full members, a limit of one member per company. Seniority within a company is not an issue – all we ask is that members have a wide knowledge of IMS data & systems on an international basis (where international means more than 5 countries).
The Committee meets twice a year. One meeting is organised within the frame of the yearly EphMRA conference and usually lasts 1.5 days. The second meeting is a one day interim meeting usually taking place in the first quarter of a year. The location for the interim meeting varies depending on the host.